Literature DB >> 9988316

Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand.

A Brockman1, R E Paul, T J Anderson, I Hackford, L Phaiphun, S Looareesuwan, F Nosten, K P Day.   

Abstract

Parasite genotyping by the polymerase chain reaction was used to distinguish recrudescent from newly acquired Plasmodium falciparum infections in a Karen population resident on the northwestern border of Thailand where malaria transmission is low (one infection/person/year). Plasmodium falciparum infections were genotyped for allelic variation in three polymorphic antigen loci, merozoite surface proteins-1 and -2 (MSP-1 and -2) and glutamaterich protein (GLURP), before and after antimalarial drug treatment. Population genotype frequencies were measured to provide the baseline information to calculate the probability of a new infection with a different or the same genotype to the initial pretreatment isolate. Overall, 38% of the infections detected following treatment had an identical genotype before and up to 121 days after treatment. These post-treatment genotypes were considered recrudescent because of the low (< 5%) probability of repeated occurrence by chance in the same patient. This approach allows studies of antimalarial drug treatment to be conducted in areas of low transmission since recrudescences can be distinguished confidently from newly acquired infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988316     DOI: 10.4269/ajtmh.1999.60.14

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  65 in total

1.  Evidence for intragenic recombination in Plasmodium falciparum: identification of a novel allele family in block 2 of merozoite surface protein-1: Asembo Bay Area Cohort Project XIV.

Authors:  Shannon Takala; OraLee Branch; Ananias A Escalante; Simon Kariuki; John Wootton; Altaf A Lal
Journal:  Mol Biochem Parasitol       Date:  2002 Nov-Dec       Impact factor: 1.759

Review 2.  History, dynamics, and public health importance of malaria parasite resistance.

Authors:  Ambrose O Talisuna; Peter Bloland; Umberto D'Alessandro
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

3.  In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up.

Authors:  Kasia Stepniewska; Walter R J Taylor; Mayfong Mayxay; Ric Price; Frank Smithuis; Jean-Paul Guthmann; Karen Barnes; Hla Yin Myint; Martin Adjuik; Piero Olliaro; Sasithon Pukrittayakamee; Sornchai Looareesuwan; Tran Tinh Hien; Jeremy Farrar; François Nosten; Nicholas P J Day; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

4.  The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.

Authors:  Rose McGready; Kasia Stepniewska; Niklas Lindegardh; Elizabeth A Ashley; Yar La; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Eur J Clin Pharmacol       Date:  2006-10-20       Impact factor: 2.953

5.  Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials.

Authors:  Bryan Greenhouse; Christian Dokomajilar; Alan Hubbard; Philip J Rosenthal; Grant Dorsey
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191

6.  Can estimates of antimalarial efficacy from field studies be improved?

Authors:  Michelle L Gatton; Qin Cheng
Journal:  Trends Parasitol       Date:  2008-01-07

7.  Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria.

Authors:  Ric N Price; Anne-Catrin Uhlemann; Michele van Vugt; Al Brockman; Robert Hutagalung; Shalini Nair; Denae Nash; Pratap Singhasivanon; Tim J C Anderson; Sanjeev Krishna; Nicholas J White; François Nosten
Journal:  Clin Infect Dis       Date:  2006-04-26       Impact factor: 9.079

8.  A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy.

Authors:  Rose McGready; Saw Oo Tan; Elizabeth A Ashley; Mupawjay Pimanpanarak; Jacher Viladpai-Nguen; Lucy Phaiphun; Katja Wüstefeld; Marion Barends; Natthapon Laochan; Lily Keereecharoen; Niklas Lindegardh; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  PLoS Med       Date:  2008-12-23       Impact factor: 11.069

9.  Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women.

Authors:  Alfredo Mayor; Elisa Serra-Casas; Azucena Bardají; Sergi Sanz; Laura Puyol; Pau Cisteró; Betuel Sigauque; Inacio Mandomando; John J Aponte; Pedro L Alonso; Clara Menéndez
Journal:  Malar J       Date:  2009-01-09       Impact factor: 2.979

10.  Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis.

Authors:  Julien Zwang; Elizabeth A Ashley; Corine Karema; Umberto D'Alessandro; Frank Smithuis; Grant Dorsey; Bart Janssens; Mayfong Mayxay; Paul Newton; Pratap Singhasivanon; Kasia Stepniewska; Nicholas J White; François Nosten
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.